<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519089</url>
  </required_header>
  <id_info>
    <org_study_id>A3921137</org_study_id>
    <nct_id>NCT01519089</nct_id>
  </id_info>
  <brief_title>A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis</brief_title>
  <official_title>A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the long term safety of CP-690,550 in
      patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
      This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10
      mg BID) after 16 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adjudicated Cardiovacular Events</measure>
    <time_frame>Baseline to Follow-up</time_frame>
    <description>Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Malignancy Events _Week 0 Through Follow-up</measure>
    <time_frame>Baseline to Follow-up</time_frame>
    <description>For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</measure>
    <time_frame>Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score &gt;= 125 Percent of the Baseline PASI Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</measure>
    <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16</measure>
    <time_frame>Week 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</measure>
    <time_frame>Week 20, 28, 40, 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</measure>
    <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Affected Nails</measure>
    <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Severity Item (ISI) Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score</measure>
    <time_frame>Week (W) 16, 28, 52</time_frame>
    <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score</measure>
    <time_frame>Week 16, 28, 52</time_frame>
    <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitation Questionnaire (WLQ)</measure>
    <time_frame>Baseline (BL), Week (W) 4, 16, 28, 52</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Pain Assessment (JPA)</measure>
    <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
    <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to &quot;select the number that best describes any joint pain that participant may have experienced over the past 24 hours&quot; with response options ranging from &quot;0-no joint pain&quot; to &quot;10-worst possible joint pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Subjects answered the following question, &quot;Considering the possible effects of the arthritis, how are you feeling today?&quot; The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>CP-690,550 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP690,550 5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.</description>
    <arm_group_label>CP-690,550 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690, 550</intervention_name>
    <description>5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.</description>
    <arm_group_label>CP690,550 5 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are 20 years or older and considered to be candidates for systemic or phototherapy.

        [Moderate to Severe Plaque Psoriasis]

          -  Diagnosed for at least 12 months.

          -  Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis
             covering at least 10% of body surface area (BSA).

        [Psoriatic Arthritis]

          -  Diagnosed for at least 6 months.

          -  Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at
             screening;

          -  Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and
             active plaque psoriasis with at least 2 cm in diameter.

        Exclusion Criteria:

          -  Non-plaque or drug induced forms of psoriasis

          -  Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic
             arthritis or cannot discontinue phototherapy (PUVA or UVB)

          -  any uncontrolled significant medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JR Sapporo hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Chuo-ku, Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical University Hospital</name>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>324-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Teishin Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo medical university Hachioji medical center</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Medical Center NTT East Corporation</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tonami General Hospital</name>
      <address>
        <city>Tonami</city>
        <state>Toyama</state>
        <zip>939-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Yamanashi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nissay Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>550-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921137&amp;StudyName=A%20Long%20Term%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Efficacy%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Plaque%20Psori</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>August 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2015</results_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic</keyword>
  <keyword>severe</keyword>
  <keyword>moderate</keyword>
  <keyword>treatment</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>Plaque psoriasis</keyword>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>tofacitinib</keyword>
  <keyword>Xeljanz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not received study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="11.8"/>
                    <measurement group_id="B2" value="46.4" spread="10.8"/>
                    <measurement group_id="B3" value="48.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 16</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adjudicated Cardiovacular Events</title>
        <description>Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.</description>
        <time_frame>Baseline to Follow-up</time_frame>
        <population>Participants treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Cardiovacular Events</title>
          <description>Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.</description>
          <population>Participants treated with at least 1 dose of study drugs.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Malignancy Events _Week 0 Through Follow-up</title>
        <description>For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist’s report to the central laboratory for a blinded review by a central pathologist.</description>
        <time_frame>Baseline to Follow-up</time_frame>
        <population>Participants treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Malignancy Events _Week 0 Through Follow-up</title>
          <description>For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist’s report to the central laboratory for a blinded review by a central pathologist.</description>
          <population>Participants treated with at least 1 dose of study drugs.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with any malignancy events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancy excluding non-melanoma skin cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma/Lymphoproliferative disorders (LPD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Melanoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-melanoma skin cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
        <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="70.5"/>
                    <measurement group_id="O3" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="65.9"/>
                    <measurement group_id="O3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4"/>
                    <measurement group_id="O2" value="84.1"/>
                    <measurement group_id="O3" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7"/>
                    <measurement group_id="O2" value="79.5"/>
                    <measurement group_id="O3" value="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4"/>
                    <measurement group_id="O2" value="79.5"/>
                    <measurement group_id="O3" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="8.0">The 95 percent confidence interval could not be constructed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="8.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="12.0" lower_limit="8.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="8.0" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Week 16</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Week</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="12.0">The median time could not be computed because fewer than half of the subjects achieved a PASI90 response.</measurement>
                    <measurement group_id="O2" value="12.0" lower_limit="12.0" upper_limit="16.0"/>
                    <measurement group_id="O3" value="16.0" lower_limit="12.0">The 95 percent upper limit could not be computed due to the limited analysis duration up to Week 16.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score &gt;= 125 Percent of the Baseline PASI Score</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score &gt;= 125 Percent of the Baseline PASI Score</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.18" spread="5.898"/>
                    <measurement group_id="O2" value="-7.36" spread="6.428"/>
                    <measurement group_id="O3" value="-6.28" spread="6.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.40" spread="7.518"/>
                    <measurement group_id="O2" value="-13.16" spread="8.739"/>
                    <measurement group_id="O3" value="-11.79" spread="8.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.95" spread="8.392"/>
                    <measurement group_id="O2" value="-19.90" spread="10.741"/>
                    <measurement group_id="O3" value="-17.88" spread="9.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.91" spread="8.918"/>
                    <measurement group_id="O2" value="-21.68" spread="11.598"/>
                    <measurement group_id="O3" value="-20.26" spread="10.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.53" spread="9.094"/>
                    <measurement group_id="O2" value="-22.06" spread="12.606"/>
                    <measurement group_id="O3" value="-20.75" spread="10.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.95" spread="9.239"/>
                    <measurement group_id="O2" value="-22.18" spread="12.045"/>
                    <measurement group_id="O3" value="-21.53" spread="10.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.77" spread="10.196"/>
                    <measurement group_id="O2" value="-21.46" spread="10.503"/>
                    <measurement group_id="O3" value="-21.62" spread="10.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.20" spread="10.181"/>
                    <measurement group_id="O2" value="-21.18" spread="10.229"/>
                    <measurement group_id="O3" value="-21.71" spread="10.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.96" spread="9.621"/>
                    <measurement group_id="O2" value="-22.11" spread="10.598"/>
                    <measurement group_id="O3" value="-22.03" spread="10.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, “lesion severity” and the “percent of body surface area (BSA)” affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, “lesion severity” and the “percent of body surface area (BSA)” affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: Erythema (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.83"/>
                    <measurement group_id="O2" value="-0.9" spread="0.82"/>
                    <measurement group_id="O3" value="-0.7" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.67"/>
                    <measurement group_id="O2" value="-0.8" spread="0.72"/>
                    <measurement group_id="O3" value="-0.6" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.67"/>
                    <measurement group_id="O2" value="-0.8" spread="0.69"/>
                    <measurement group_id="O3" value="-0.7" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.69"/>
                    <measurement group_id="O2" value="-0.8" spread="0.71"/>
                    <measurement group_id="O3" value="-0.7" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.70"/>
                    <measurement group_id="O2" value="-0.8" spread="0.89"/>
                    <measurement group_id="O3" value="-0.6" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.63"/>
                    <measurement group_id="O2" value="-0.6" spread="0.75"/>
                    <measurement group_id="O3" value="-0.6" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.63"/>
                    <measurement group_id="O2" value="-0.7" spread="0.59"/>
                    <measurement group_id="O3" value="-0.6" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.67"/>
                    <measurement group_id="O2" value="-0.7" spread="0.71"/>
                    <measurement group_id="O3" value="-0.6" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.66"/>
                    <measurement group_id="O2" value="-0.9" spread="0.91"/>
                    <measurement group_id="O3" value="-0.7" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.59"/>
                    <measurement group_id="O2" value="-0.8" spread="0.74"/>
                    <measurement group_id="O3" value="-0.6" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.57"/>
                    <measurement group_id="O2" value="-0.8" spread="0.76"/>
                    <measurement group_id="O3" value="-0.6" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.70"/>
                    <measurement group_id="O2" value="-0.7" spread="0.73"/>
                    <measurement group_id="O3" value="-0.6" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.02"/>
                    <measurement group_id="O2" value="-1.3" spread="0.99"/>
                    <measurement group_id="O3" value="-1.0" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.81"/>
                    <measurement group_id="O2" value="-1.2" spread="0.94"/>
                    <measurement group_id="O3" value="-1.1" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.64"/>
                    <measurement group_id="O2" value="-1.3" spread="0.79"/>
                    <measurement group_id="O3" value="-1.1" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.91"/>
                    <measurement group_id="O2" value="-1.2" spread="0.79"/>
                    <measurement group_id="O3" value="-1.2" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.89"/>
                    <measurement group_id="O2" value="-1.2" spread="1.09"/>
                    <measurement group_id="O3" value="-1.0" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.86"/>
                    <measurement group_id="O2" value="-1.0" spread="0.85"/>
                    <measurement group_id="O3" value="-1.0" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.80"/>
                    <measurement group_id="O2" value="-1.3" spread="0.82"/>
                    <measurement group_id="O3" value="-1.1" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.90"/>
                    <measurement group_id="O2" value="-1.2" spread="0.98"/>
                    <measurement group_id="O3" value="-1.1" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Head/Neck)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.86"/>
                    <measurement group_id="O2" value="-1.2" spread="0.99"/>
                    <measurement group_id="O3" value="-1.0" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Upper Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.70"/>
                    <measurement group_id="O2" value="-1.2" spread="0.86"/>
                    <measurement group_id="O3" value="-1.0" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Trunk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.71"/>
                    <measurement group_id="O2" value="-1.3" spread="0.95"/>
                    <measurement group_id="O3" value="-1.1" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Lower Limbs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.72"/>
                    <measurement group_id="O2" value="-1.3" spread="0.96"/>
                    <measurement group_id="O3" value="-1.1" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.13"/>
                    <measurement group_id="O2" value="-1.6" spread="1.03"/>
                    <measurement group_id="O3" value="-1.5" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.93"/>
                    <measurement group_id="O2" value="-1.6" spread="0.98"/>
                    <measurement group_id="O3" value="-1.5" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.91"/>
                    <measurement group_id="O2" value="-1.9" spread="0.93"/>
                    <measurement group_id="O3" value="-1.8" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.91"/>
                    <measurement group_id="O2" value="-1.7" spread="0.91"/>
                    <measurement group_id="O3" value="-1.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.91"/>
                    <measurement group_id="O2" value="-1.6" spread="1.10"/>
                    <measurement group_id="O3" value="-1.4" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.93"/>
                    <measurement group_id="O2" value="-1.6" spread="0.89"/>
                    <measurement group_id="O3" value="-1.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.98"/>
                    <measurement group_id="O2" value="-1.7" spread="1.03"/>
                    <measurement group_id="O3" value="-1.7" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.91"/>
                    <measurement group_id="O2" value="-1.7" spread="0.98"/>
                    <measurement group_id="O3" value="-1.7" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.90"/>
                    <measurement group_id="O2" value="-1.5" spread="1.03"/>
                    <measurement group_id="O3" value="-1.4" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.80"/>
                    <measurement group_id="O2" value="-1.6" spread="0.86"/>
                    <measurement group_id="O3" value="-1.5" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.82"/>
                    <measurement group_id="O2" value="-1.8" spread="1.00"/>
                    <measurement group_id="O3" value="-1.6" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.82"/>
                    <measurement group_id="O2" value="-1.8" spread="0.88"/>
                    <measurement group_id="O3" value="-1.5" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.10"/>
                    <measurement group_id="O2" value="-1.7" spread="0.98"/>
                    <measurement group_id="O3" value="-1.7" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.99"/>
                    <measurement group_id="O2" value="-1.8" spread="1.13"/>
                    <measurement group_id="O3" value="-1.8" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.08"/>
                    <measurement group_id="O2" value="-2.0" spread="0.95"/>
                    <measurement group_id="O3" value="-2.0" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.92"/>
                    <measurement group_id="O2" value="-1.9" spread="0.94"/>
                    <measurement group_id="O3" value="-1.9" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.94"/>
                    <measurement group_id="O2" value="-1.6" spread="1.12"/>
                    <measurement group_id="O3" value="-1.6" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.94"/>
                    <measurement group_id="O2" value="-1.8" spread="0.99"/>
                    <measurement group_id="O3" value="-1.7" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.01"/>
                    <measurement group_id="O2" value="-2.0" spread="1.00"/>
                    <measurement group_id="O3" value="-2.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.91"/>
                    <measurement group_id="O2" value="-1.9" spread="1.06"/>
                    <measurement group_id="O3" value="-1.9" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Head/Neck) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.92"/>
                    <measurement group_id="O2" value="-1.6" spread="1.02"/>
                    <measurement group_id="O3" value="-1.6" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Upper Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.91"/>
                    <measurement group_id="O2" value="-1.7" spread="0.95"/>
                    <measurement group_id="O3" value="-1.6" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Trunk) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.05"/>
                    <measurement group_id="O2" value="-1.9" spread="1.00"/>
                    <measurement group_id="O3" value="-1.7" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Lower Limbs) (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.85"/>
                    <measurement group_id="O2" value="-1.9" spread="1.00"/>
                    <measurement group_id="O3" value="-1.7" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Head/Neck) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.14"/>
                    <measurement group_id="O2" value="-1.7" spread="1.07"/>
                    <measurement group_id="O3" value="-1.7" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Upper Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.13"/>
                    <measurement group_id="O2" value="-1.9" spread="1.12"/>
                    <measurement group_id="O3" value="-1.9" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Trunk) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.10"/>
                    <measurement group_id="O2" value="-2.0" spread="1.07"/>
                    <measurement group_id="O3" value="-2.0" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Lower Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.03"/>
                    <measurement group_id="O2" value="-1.9" spread="0.94"/>
                    <measurement group_id="O3" value="-2.0" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Head/Neck) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.96"/>
                    <measurement group_id="O2" value="-1.6" spread="1.17"/>
                    <measurement group_id="O3" value="-1.6" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Upper Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.96"/>
                    <measurement group_id="O2" value="-1.8" spread="1.01"/>
                    <measurement group_id="O3" value="-1.8" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Trunk) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.01"/>
                    <measurement group_id="O2" value="-2.0" spread="1.01"/>
                    <measurement group_id="O3" value="-2.0" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Lower Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.95"/>
                    <measurement group_id="O2" value="-2.0" spread="1.08"/>
                    <measurement group_id="O3" value="-2.0" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Head/Neck) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.95"/>
                    <measurement group_id="O2" value="-1.6" spread="1.08"/>
                    <measurement group_id="O3" value="-1.6" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Upper Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.93"/>
                    <measurement group_id="O2" value="-1.7" spread="1.05"/>
                    <measurement group_id="O3" value="-1.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Trunk) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.96"/>
                    <measurement group_id="O2" value="-1.8" spread="1.09"/>
                    <measurement group_id="O3" value="-1.7" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Lower Limbs) (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.93"/>
                    <measurement group_id="O2" value="-1.8" spread="1.06"/>
                    <measurement group_id="O3" value="-1.7" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.15"/>
                    <measurement group_id="O2" value="-1.6" spread="0.96"/>
                    <measurement group_id="O3" value="-1.7" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.97"/>
                    <measurement group_id="O2" value="-1.9" spread="1.26"/>
                    <measurement group_id="O3" value="-1.9" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.04"/>
                    <measurement group_id="O2" value="-2.1" spread="1.04"/>
                    <measurement group_id="O3" value="-2.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.04"/>
                    <measurement group_id="O2" value="-2.1" spread="1.09"/>
                    <measurement group_id="O3" value="-2.1" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.00"/>
                    <measurement group_id="O2" value="-1.5" spread="1.12"/>
                    <measurement group_id="O3" value="-1.6" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.97"/>
                    <measurement group_id="O2" value="-1.7" spread="1.14"/>
                    <measurement group_id="O3" value="-1.8" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.01"/>
                    <measurement group_id="O2" value="-1.9" spread="1.07"/>
                    <measurement group_id="O3" value="-2.0" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.95"/>
                    <measurement group_id="O2" value="-2.0" spread="1.06"/>
                    <measurement group_id="O3" value="-2.1" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.94"/>
                    <measurement group_id="O2" value="-1.5" spread="1.05"/>
                    <measurement group_id="O3" value="-1.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.96"/>
                    <measurement group_id="O2" value="-1.6" spread="1.14"/>
                    <measurement group_id="O3" value="-1.5" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.93"/>
                    <measurement group_id="O2" value="-1.8" spread="1.05"/>
                    <measurement group_id="O3" value="-1.8" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.92"/>
                    <measurement group_id="O2" value="-1.8" spread="1.16"/>
                    <measurement group_id="O3" value="-1.8" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.11"/>
                    <measurement group_id="O2" value="-1.6" spread="0.81"/>
                    <measurement group_id="O3" value="-1.7" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.09"/>
                    <measurement group_id="O2" value="-1.8" spread="1.07"/>
                    <measurement group_id="O3" value="-2.0" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.13"/>
                    <measurement group_id="O2" value="-2.0" spread="0.99"/>
                    <measurement group_id="O3" value="-2.1" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.05"/>
                    <measurement group_id="O2" value="-1.9" spread="0.99"/>
                    <measurement group_id="O3" value="-2.1" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.97"/>
                    <measurement group_id="O2" value="-1.6" spread="0.99"/>
                    <measurement group_id="O3" value="-1.6" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.12"/>
                    <measurement group_id="O2" value="-1.7" spread="1.10"/>
                    <measurement group_id="O3" value="-1.9" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.12"/>
                    <measurement group_id="O2" value="-1.8" spread="1.16"/>
                    <measurement group_id="O3" value="-1.9" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.03"/>
                    <measurement group_id="O2" value="-1.8" spread="1.14"/>
                    <measurement group_id="O3" value="-2.0" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Head/Neck) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.01"/>
                    <measurement group_id="O2" value="-1.4" spread="1.07"/>
                    <measurement group_id="O3" value="-1.6" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Upper Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.05"/>
                    <measurement group_id="O2" value="-1.6" spread="1.02"/>
                    <measurement group_id="O3" value="-1.7" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Trunk) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.99"/>
                    <measurement group_id="O2" value="-1.8" spread="1.11"/>
                    <measurement group_id="O3" value="-1.7" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Lower Limbs) (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.09"/>
                    <measurement group_id="O2" value="-1.7" spread="1.02"/>
                    <measurement group_id="O3" value="-1.7" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Head/Neck) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.10"/>
                    <measurement group_id="O2" value="-1.7" spread="0.90"/>
                    <measurement group_id="O3" value="-1.8" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Upper Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.05"/>
                    <measurement group_id="O2" value="-1.9" spread="1.06"/>
                    <measurement group_id="O3" value="-2.0" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Trunk) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.04"/>
                    <measurement group_id="O2" value="-2.2" spread="0.87"/>
                    <measurement group_id="O3" value="-2.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Lower Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.05"/>
                    <measurement group_id="O2" value="-2.0" spread="1.03"/>
                    <measurement group_id="O3" value="-2.2" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Head/Neck) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.05"/>
                    <measurement group_id="O2" value="-1.5" spread="1.08"/>
                    <measurement group_id="O3" value="-1.6" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Upper Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.18"/>
                    <measurement group_id="O2" value="-1.8" spread="0.98"/>
                    <measurement group_id="O3" value="-1.9" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Trunk) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.26"/>
                    <measurement group_id="O2" value="-2.1" spread="0.93"/>
                    <measurement group_id="O3" value="-2.1" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Lower Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.14"/>
                    <measurement group_id="O2" value="-1.9" spread="1.03"/>
                    <measurement group_id="O3" value="-2.1" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Head/Neck) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.97"/>
                    <measurement group_id="O2" value="-1.4" spread="1.00"/>
                    <measurement group_id="O3" value="-1.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Upper Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.10"/>
                    <measurement group_id="O2" value="-1.8" spread="0.94"/>
                    <measurement group_id="O3" value="-1.7" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Trunk) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.93"/>
                    <measurement group_id="O2" value="-1.9" spread="1.03"/>
                    <measurement group_id="O3" value="-1.8" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Lower Limbs) (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.11"/>
                    <measurement group_id="O2" value="-1.8" spread="1.06"/>
                    <measurement group_id="O3" value="-1.8" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Head/Neck) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.17"/>
                    <measurement group_id="O2" value="-1.6" spread="1.24"/>
                    <measurement group_id="O3" value="-1.8" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Upper Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.15"/>
                    <measurement group_id="O2" value="-2.0" spread="0.90"/>
                    <measurement group_id="O3" value="-2.0" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Trunk) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.01"/>
                    <measurement group_id="O2" value="-2.2" spread="0.93"/>
                    <measurement group_id="O3" value="-2.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Lower Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.11"/>
                    <measurement group_id="O2" value="-2.2" spread="0.94"/>
                    <measurement group_id="O3" value="-2.1" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Head/Neck) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.06"/>
                    <measurement group_id="O2" value="-1.5" spread="1.22"/>
                    <measurement group_id="O3" value="-1.6" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Upper Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.21"/>
                    <measurement group_id="O2" value="-2.0" spread="0.97"/>
                    <measurement group_id="O3" value="-1.9" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Trunk) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.39"/>
                    <measurement group_id="O2" value="-2.1" spread="1.03"/>
                    <measurement group_id="O3" value="-2.0" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Lower Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.29"/>
                    <measurement group_id="O2" value="-2.2" spread="0.97"/>
                    <measurement group_id="O3" value="-2.1" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Head/Neck) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.98"/>
                    <measurement group_id="O2" value="-1.6" spread="1.08"/>
                    <measurement group_id="O3" value="-1.7" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Upper Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.02"/>
                    <measurement group_id="O2" value="-1.9" spread="0.98"/>
                    <measurement group_id="O3" value="-1.7" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Trunk) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.96"/>
                    <measurement group_id="O2" value="-1.9" spread="1.01"/>
                    <measurement group_id="O3" value="-1.7" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Lower Limbs) (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.15"/>
                    <measurement group_id="O2" value="-2.0" spread="1.03"/>
                    <measurement group_id="O3" value="-1.8" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="38.6"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="61.4"/>
                    <measurement group_id="O3" value="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1"/>
                    <measurement group_id="O2" value="59.1"/>
                    <measurement group_id="O3" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Almost Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mild (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Severe (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Almost Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Clear (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Almost Clear (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mild (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Moderate (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Severe (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Almost Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mild (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Moderate (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Severe(n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Almost Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mild (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Moderate (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Severe (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Clear (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="34.2"/>
                    <measurement group_id="O3" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Almost Clear (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Mild (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Moderate (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="7.9"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Severe (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Clear (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Almost Clear (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mild (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Moderate (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Severe (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.</description>
        <time_frame>Week 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="78.1"/>
                    <measurement group_id="O3" value="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="71.9"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.</description>
        <time_frame>Week 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="73.3"/>
                    <measurement group_id="O3" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
        <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=32, 28, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="9.63"/>
                    <measurement group_id="O2" value="-1.8" spread="7.72"/>
                    <measurement group_id="O3" value="-2.6" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=32, 28, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="15.27"/>
                    <measurement group_id="O2" value="-9.4" spread="12.66"/>
                    <measurement group_id="O3" value="-10.4" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=32, 27, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="15.29"/>
                    <measurement group_id="O2" value="-14.1" spread="13.03"/>
                    <measurement group_id="O3" value="-14.6" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=32, 27, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="15.83"/>
                    <measurement group_id="O2" value="-16.4" spread="15.27"/>
                    <measurement group_id="O3" value="-18.9" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=31, 26, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" spread="16.18"/>
                    <measurement group_id="O2" value="-16.2" spread="14.13"/>
                    <measurement group_id="O3" value="-19.5" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=30, 22, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="15.16"/>
                    <measurement group_id="O2" value="-16.2" spread="15.62"/>
                    <measurement group_id="O3" value="-18.7" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Affected Nails</title>
        <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
        <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Affected Nails</title>
          <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>nails</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" spread="2.82"/>
                    <measurement group_id="O2" value="7.13" spread="3.07"/>
                    <measurement group_id="O3" value="7.55" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=32, 28, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread="3.17"/>
                    <measurement group_id="O2" value="7.11" spread="3.02"/>
                    <measurement group_id="O3" value="7.40" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=32, 28, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="3.43"/>
                    <measurement group_id="O2" value="5.75" spread="3.56"/>
                    <measurement group_id="O3" value="6.37" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=32, 27, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="3.60"/>
                    <measurement group_id="O2" value="4.59" spread="4.02"/>
                    <measurement group_id="O3" value="5.44" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=32, 27, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="3.87"/>
                    <measurement group_id="O2" value="3.59" spread="3.96"/>
                    <measurement group_id="O3" value="4.10" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=31, 26, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="3.94"/>
                    <measurement group_id="O2" value="3.77" spread="3.81"/>
                    <measurement group_id="O3" value="3.53" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=30, 22, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="4.25"/>
                    <measurement group_id="O2" value="2.50" spread="3.07"/>
                    <measurement group_id="O3" value="3.21" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itch Severity Item (ISI) Score</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Itch Severity Item (ISI) Score</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="2.669"/>
                    <measurement group_id="O2" value="5.32" spread="2.967"/>
                    <measurement group_id="O3" value="5.74" spread="2.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="2.797"/>
                    <measurement group_id="O2" value="3.30" spread="2.530"/>
                    <measurement group_id="O3" value="4.23" spread="2.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="2.379"/>
                    <measurement group_id="O2" value="2.27" spread="2.472"/>
                    <measurement group_id="O3" value="2.95" spread="2.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="2.381"/>
                    <measurement group_id="O2" value="1.22" spread="1.739"/>
                    <measurement group_id="O3" value="1.75" spread="2.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="2.379"/>
                    <measurement group_id="O2" value="1.20" spread="1.833"/>
                    <measurement group_id="O3" value="1.49" spread="2.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="2.378"/>
                    <measurement group_id="O2" value="0.90" spread="1.257"/>
                    <measurement group_id="O3" value="1.30" spread="1.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.618"/>
                    <measurement group_id="O2" value="1.28" spread="1.589"/>
                    <measurement group_id="O3" value="1.11" spread="1.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.651"/>
                    <measurement group_id="O2" value="1.62" spread="2.196"/>
                    <measurement group_id="O3" value="1.35" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="1.814"/>
                    <measurement group_id="O2" value="1.13" spread="1.848"/>
                    <measurement group_id="O3" value="1.01" spread="1.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="2.084"/>
                    <measurement group_id="O2" value="0.91" spread="1.329"/>
                    <measurement group_id="O3" value="1.04" spread="1.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Score</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Score</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="6.25"/>
                    <measurement group_id="O2" value="8.6" spread="5.91"/>
                    <measurement group_id="O3" value="9.9" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="5.20"/>
                    <measurement group_id="O2" value="5.8" spread="5.32"/>
                    <measurement group_id="O3" value="6.8" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="5.07"/>
                    <measurement group_id="O2" value="4.2" spread="4.63"/>
                    <measurement group_id="O3" value="5.1" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.95"/>
                    <measurement group_id="O2" value="2.8" spread="3.30"/>
                    <measurement group_id="O3" value="3.4" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.86"/>
                    <measurement group_id="O2" value="1.8" spread="2.68"/>
                    <measurement group_id="O3" value="2.2" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.04"/>
                    <measurement group_id="O2" value="1.9" spread="2.73"/>
                    <measurement group_id="O3" value="2.1" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="3.13"/>
                    <measurement group_id="O2" value="1.8" spread="2.54"/>
                    <measurement group_id="O3" value="1.9" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.66"/>
                    <measurement group_id="O2" value="2.9" spread="3.68"/>
                    <measurement group_id="O3" value="2.3" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.81"/>
                    <measurement group_id="O2" value="2.3" spread="4.11"/>
                    <measurement group_id="O3" value="2.0" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.42"/>
                    <measurement group_id="O2" value="2.2" spread="4.00"/>
                    <measurement group_id="O3" value="1.9" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score</title>
        <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
        <time_frame>Week (W) 16, 28, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score</title>
          <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>W16: Physical Functioning Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.951" spread="5.1880"/>
                    <measurement group_id="O2" value="4.809" spread="9.1822"/>
                    <measurement group_id="O3" value="3.329" spread="7.4800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Role-Physical Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.160" spread="9.3615"/>
                    <measurement group_id="O2" value="5.130" spread="11.1600"/>
                    <measurement group_id="O3" value="5.664" spread="10.2172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Bodily Pain Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.808" spread="13.8431"/>
                    <measurement group_id="O2" value="10.663" spread="12.2936"/>
                    <measurement group_id="O3" value="11.256" spread="13.0524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: General Health Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.392" spread="7.0933"/>
                    <measurement group_id="O2" value="4.333" spread="7.0145"/>
                    <measurement group_id="O3" value="3.328" spread="7.0799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Vitality Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.664" spread="9.5406"/>
                    <measurement group_id="O2" value="3.517" spread="11.4421"/>
                    <measurement group_id="O3" value="4.112" spread="10.4509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Social Function Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.629" spread="9.9734"/>
                    <measurement group_id="O2" value="7.932" spread="8.8645"/>
                    <measurement group_id="O3" value="7.775" spread="9.3992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Role-Emotional Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.219" spread="11.5898"/>
                    <measurement group_id="O2" value="5.584" spread="11.5654"/>
                    <measurement group_id="O3" value="6.431" spread="11.5365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Mental Health Domain (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.928" spread="12.8757"/>
                    <measurement group_id="O2" value="5.125" spread="13.3613"/>
                    <measurement group_id="O3" value="5.541" spread="13.0378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Physical Functioning Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.571" spread="6.3446"/>
                    <measurement group_id="O2" value="4.303" spread="10.3695"/>
                    <measurement group_id="O3" value="2.870" spread="8.5558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Role-Physical Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.882" spread="10.6375"/>
                    <measurement group_id="O2" value="5.017" spread="11.4671"/>
                    <measurement group_id="O3" value="5.471" spread="10.9795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Bodily Pain Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.113" spread="15.9485"/>
                    <measurement group_id="O2" value="8.394" spread="12.5405"/>
                    <measurement group_id="O3" value="9.295" spread="14.3670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: General Health Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.644" spread="5.9230"/>
                    <measurement group_id="O2" value="3.517" spread="7.1375"/>
                    <measurement group_id="O3" value="3.059" spread="6.5025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Vitality Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.038" spread="10.0116"/>
                    <measurement group_id="O2" value="3.608" spread="10.0742"/>
                    <measurement group_id="O3" value="3.833" spread="9.9815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Social Function Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.628" spread="11.3068"/>
                    <measurement group_id="O2" value="6.205" spread="10.4347"/>
                    <measurement group_id="O3" value="6.427" spread="10.8358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Role-Emotional Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.395" spread="11.8846"/>
                    <measurement group_id="O2" value="6.310" spread="12.9504"/>
                    <measurement group_id="O3" value="6.879" spread="12.3375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Mental Health Domain (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.701" spread="12.4375"/>
                    <measurement group_id="O2" value="5.328" spread="12.8129"/>
                    <measurement group_id="O3" value="6.048" spread="12.5580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Physical Functioning Domain (n=39,32,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.151" spread="5.6134"/>
                    <measurement group_id="O2" value="3.773" spread="7.3533"/>
                    <measurement group_id="O3" value="2.882" spread="6.4585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Role-Physical Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.669" spread="10.0520"/>
                    <measurement group_id="O2" value="4.623" spread="9.7340"/>
                    <measurement group_id="O3" value="5.747" spread="9.8926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Bodily Pain Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.335" spread="12.1413"/>
                    <measurement group_id="O2" value="10.673" spread="9.7128"/>
                    <measurement group_id="O3" value="11.586" spread="11.0678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: General Health Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.758" spread="6.0866"/>
                    <measurement group_id="O2" value="4.888" spread="6.8235"/>
                    <measurement group_id="O3" value="3.718" spread="6.4707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Vitality Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.068" spread="10.5612"/>
                    <measurement group_id="O2" value="5.052" spread="8.5160"/>
                    <measurement group_id="O3" value="4.511" spread="9.6390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Social Function Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.411" spread="9.4598"/>
                    <measurement group_id="O2" value="8.402" spread="9.2577"/>
                    <measurement group_id="O3" value="8.407" spread="9.3024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Role-Emotional Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.445" spread="11.0018"/>
                    <measurement group_id="O2" value="5.915" spread="10.3091"/>
                    <measurement group_id="O3" value="7.305" spread="10.6949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Mental Health Domain (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.317" spread="11.6243"/>
                    <measurement group_id="O2" value="6.926" spread="12.6861"/>
                    <measurement group_id="O3" value="7.141" spread="12.0276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score</title>
        <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
        <time_frame>Week 16, 28, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score</title>
          <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16: Physical Health Score (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.719" spread="6.6806"/>
                    <measurement group_id="O2" value="6.146" spread="8.5192"/>
                    <measurement group_id="O3" value="5.407" spread="7.6087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mental Health Score (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.767" spread="11.0945"/>
                    <measurement group_id="O2" value="5.029" spread="11.4967"/>
                    <measurement group_id="O3" value="5.929" spread="11.2548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Physical Health Score (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.770" spread="7.7829"/>
                    <measurement group_id="O2" value="4.799" spread="8.8893"/>
                    <measurement group_id="O3" value="4.259" spread="8.2914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mental Health Score (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.085" spread="11.3660"/>
                    <measurement group_id="O2" value="5.364" spread="10.9089"/>
                    <measurement group_id="O3" value="6.266" spread="11.1159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Physical Health Score (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.676" spread="5.7405"/>
                    <measurement group_id="O2" value="5.250" spread="5.7614"/>
                    <measurement group_id="O3" value="4.935" spread="5.7159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mental Health Score (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.878" spread="10.1983"/>
                    <measurement group_id="O2" value="6.826" spread="10.5988"/>
                    <measurement group_id="O3" value="7.404" spread="10.3192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitation Questionnaire (WLQ)</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
        <time_frame>Baseline (BL), Week (W) 4, 16, 28, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitation Questionnaire (WLQ)</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL: Time Management scale (n=34, 37, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.49" spread="37.783"/>
                    <measurement group_id="O2" value="42.36" spread="33.716"/>
                    <measurement group_id="O3" value="43.38" spread="35.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Physical Demands scale (n=33, 35, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="33.522"/>
                    <measurement group_id="O2" value="78.40" spread="31.122"/>
                    <measurement group_id="O3" value="72.71" spread="32.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Mental/Interpersonal Demands Scale(n=34,38,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.61" spread="29.012"/>
                    <measurement group_id="O2" value="31.52" spread="30.930"/>
                    <measurement group_id="O3" value="30.15" spread="29.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Output Demands scale (n=33, 37, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.61" spread="26.832"/>
                    <measurement group_id="O2" value="30.27" spread="35.295"/>
                    <measurement group_id="O3" value="26.66" spread="31.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: WLQ Index Score (n=34, 38, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.55" spread="6.716"/>
                    <measurement group_id="O2" value="10.74" spread="8.045"/>
                    <measurement group_id="O3" value="10.18" spread="7.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4: Time Management scale (n=31, 36, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.32" spread="42.425"/>
                    <measurement group_id="O2" value="31.39" spread="36.715"/>
                    <measurement group_id="O3" value="33.21" spread="39.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4: Physical Demands scale (n=29, 36, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.16" spread="33.013"/>
                    <measurement group_id="O2" value="83.59" spread="29.593"/>
                    <measurement group_id="O3" value="80.72" spread="31.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4:Mental/Interpersonal Demands Scale(n=32,36,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.94" spread="26.979"/>
                    <measurement group_id="O2" value="23.39" spread="32.878"/>
                    <measurement group_id="O3" value="20.82" spread="30.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4: Output Demands scale (n=30, 36, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.50" spread="21.978"/>
                    <measurement group_id="O2" value="20.14" spread="33.306"/>
                    <measurement group_id="O3" value="17.12" spread="28.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W4: WLQ Index Score (n=32, 37, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="5.591"/>
                    <measurement group_id="O2" value="8.66" spread="7.754"/>
                    <measurement group_id="O3" value="8.00" spread="6.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Time Management scale (n=31, 35, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.07" spread="38.894"/>
                    <measurement group_id="O2" value="33.29" spread="39.182"/>
                    <measurement group_id="O3" value="34.12" spread="38.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Physical Demands scale (n=30, 32, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.60" spread="26.982"/>
                    <measurement group_id="O2" value="86.52" spread="25.548"/>
                    <measurement group_id="O3" value="84.14" spread="26.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16:Mental/Interpersonal Demands Scale(n=31,35,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="21.038"/>
                    <measurement group_id="O2" value="20.28" spread="33.419"/>
                    <measurement group_id="O3" value="17.01" spread="28.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: Output Demands scale (n=32, 33, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.88" spread="20.111"/>
                    <measurement group_id="O2" value="19.55" spread="32.485"/>
                    <measurement group_id="O3" value="15.77" spread="27.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W16: WLQ Index Score (n=32, 35, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="4.715"/>
                    <measurement group_id="O2" value="8.35" spread="7.425"/>
                    <measurement group_id="O3" value="7.65" spread="6.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Time Management scale (n=34, 34, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.68" spread="40.100"/>
                    <measurement group_id="O2" value="29.78" spread="39.092"/>
                    <measurement group_id="O3" value="34.23" spread="39.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Physical Demands scale (n=32, 34, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.02" spread="31.041"/>
                    <measurement group_id="O2" value="85.42" spread="24.730"/>
                    <measurement group_id="O3" value="80.86" spread="28.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28:Mental/Interpersonal Demands Scale(n=33,35,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.84" spread="28.242"/>
                    <measurement group_id="O2" value="16.39" spread="27.736"/>
                    <measurement group_id="O3" value="16.61" spread="27.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: Output Demands scale (n=33, 34, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.94" spread="27.408"/>
                    <measurement group_id="O2" value="14.71" spread="28.761"/>
                    <measurement group_id="O3" value="14.33" spread="27.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W28: WLQ Index Score (n=34, 36, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="6.493"/>
                    <measurement group_id="O2" value="7.26" spread="6.829"/>
                    <measurement group_id="O3" value="7.34" spread="6.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Time Management scale (n=31, 31, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.32" spread="43.683"/>
                    <measurement group_id="O2" value="31.88" spread="40.686"/>
                    <measurement group_id="O3" value="41.10" spread="42.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Physical Demands scale (n=29, 29, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.16" spread="30.205"/>
                    <measurement group_id="O2" value="89.74" spread="24.410"/>
                    <measurement group_id="O3" value="83.95" spread="27.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52:Mental/Interpersonal Demands Scale(n=30,30,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.56" spread="36.007"/>
                    <measurement group_id="O2" value="16.89" spread="27.293"/>
                    <measurement group_id="O3" value="21.22" spread="31.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: Output Demands scale (n=30, 29, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.63" spread="33.750"/>
                    <measurement group_id="O2" value="12.24" spread="24.589"/>
                    <measurement group_id="O3" value="17.52" spread="29.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W52: WLQ Index Score (n=32, 31, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.44" spread="8.127"/>
                    <measurement group_id="O2" value="7.34" spread="6.429"/>
                    <measurement group_id="O3" value="8.41" spread="7.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
          <population>Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Clear (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Almost Clear (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe (n=43, 43, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Almost Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mild (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Severe (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Almost Clear (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe (n=43, 41, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Clear (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Almost Clear (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mild (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Moderate (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Severe (n=43, 40, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Almost Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mild (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Moderate (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Severe (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Almost Clear (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mild (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Moderate (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Severe (n=43, 39, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Clear (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="18.4"/>
                    <measurement group_id="O3" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Almost Clear (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Mild (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="18.4"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Moderate (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Severe (n=41, 38, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Clear (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Almost Clear (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mild (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Moderate (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Severe (n=39, 32, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Joint Pain Assessment (JPA)</title>
        <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to “select the number that best describes any joint pain that participant may have experienced over the past 24 hours” with response options ranging from “0-no joint pain” to “10-worst possible joint pain.”</description>
        <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
        <population>The subjects with a medical history of ongoing psoriatic arthritis (that was defined as the MedDRA preferred term for psoriatic arthropathy regardless of meeting the inclusion criteria for the psoriatic arthritis) in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Joint Pain Assessment (JPA)</title>
          <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to “select the number that best describes any joint pain that participant may have experienced over the past 24 hours” with response options ranging from “0-no joint pain” to “10-worst possible joint pain.”</description>
          <population>The subjects with a medical history of ongoing psoriatic arthritis (that was defined as the MedDRA preferred term for psoriatic arthropathy regardless of meeting the inclusion criteria for the psoriatic arthritis) in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="3.327"/>
                    <measurement group_id="O2" value="4.60" spread="2.558"/>
                    <measurement group_id="O3" value="4.83" spread="2.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=8, 14, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="2.726"/>
                    <measurement group_id="O2" value="1.36" spread="1.008"/>
                    <measurement group_id="O3" value="2.32" spread="2.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=8, 15, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="2.295"/>
                    <measurement group_id="O2" value="0.60" spread="0.737"/>
                    <measurement group_id="O3" value="1.04" spread="1.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=8, 14, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.753"/>
                    <measurement group_id="O2" value="0.86" spread="0.949"/>
                    <measurement group_id="O3" value="1.18" spread="1.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=4, 13, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.577"/>
                    <measurement group_id="O2" value="0.54" spread="0.660"/>
                    <measurement group_id="O3" value="0.53" spread="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 2, 4, 8, 12, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in tender joint count; &gt;=50% improvement in swollen joint count; and &gt;=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in tender joint count; &gt;=70% improvement in swollen joint count; and &gt;=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count</title>
        <description>Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count</title>
          <description>Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Tender/painful joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.50"/>
                    <measurement group_id="O2" value="-3.5" spread="2.78"/>
                    <measurement group_id="O3" value="-2.9" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="6.70"/>
                    <measurement group_id="O2" value="-9.3" spread="11.37"/>
                    <measurement group_id="O3" value="-8.3" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="10.08"/>
                    <measurement group_id="O2" value="-11.6" spread="10.24"/>
                    <measurement group_id="O3" value="-11.6" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="10.78"/>
                    <measurement group_id="O2" value="-12.5" spread="11.95"/>
                    <measurement group_id="O3" value="-12.9" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="9.59"/>
                    <measurement group_id="O2" value="-13.0" spread="12.17"/>
                    <measurement group_id="O3" value="-13.0" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="9.11"/>
                    <measurement group_id="O2" value="-12.4" spread="12.87"/>
                    <measurement group_id="O3" value="-13.0" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="9.38"/>
                    <measurement group_id="O2" value="-12.4" spread="12.52"/>
                    <measurement group_id="O3" value="-12.9" spread="11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="10.14"/>
                    <measurement group_id="O2" value="-13.4" spread="12.09"/>
                    <measurement group_id="O3" value="-13.7" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="9.24"/>
                    <measurement group_id="O2" value="-13.5" spread="12.08"/>
                    <measurement group_id="O3" value="-12.9" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count</title>
        <description>Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count</title>
          <description>Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.22"/>
                    <measurement group_id="O2" value="-3.8" spread="5.55"/>
                    <measurement group_id="O3" value="-3.1" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="4.69"/>
                    <measurement group_id="O2" value="-5.3" spread="5.80"/>
                    <measurement group_id="O3" value="-5.2" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="7.35"/>
                    <measurement group_id="O2" value="-6.4" spread="4.37"/>
                    <measurement group_id="O3" value="-6.3" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="6.35"/>
                    <measurement group_id="O2" value="-7.0" spread="4.44"/>
                    <measurement group_id="O3" value="-6.8" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="7.85"/>
                    <measurement group_id="O2" value="-7.8" spread="3.85"/>
                    <measurement group_id="O3" value="-7.6" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="8.00"/>
                    <measurement group_id="O2" value="-8.9" spread="4.42"/>
                    <measurement group_id="O3" value="-8.3" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="7.85"/>
                    <measurement group_id="O2" value="-7.6" spread="4.03"/>
                    <measurement group_id="O3" value="-7.5" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="7.85"/>
                    <measurement group_id="O2" value="-8.8" spread="4.20"/>
                    <measurement group_id="O3" value="-8.3" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="0.00"/>
                    <measurement group_id="O2" value="-8.8" spread="4.13"/>
                    <measurement group_id="O3" value="-7.2" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain</title>
        <description>Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain</title>
          <description>Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="8.30"/>
                    <measurement group_id="O2" value="-29.5" spread="23.40"/>
                    <measurement group_id="O3" value="-24.1" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="23.41"/>
                    <measurement group_id="O2" value="-41.4" spread="25.29"/>
                    <measurement group_id="O3" value="-31.9" spread="27.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="19.78"/>
                    <measurement group_id="O2" value="-43.6" spread="22.68"/>
                    <measurement group_id="O3" value="-34.4" spread="24.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5" spread="19.71"/>
                    <measurement group_id="O2" value="-46.0" spread="23.42"/>
                    <measurement group_id="O3" value="-42.2" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="15.22"/>
                    <measurement group_id="O2" value="-46.0" spread="22.44"/>
                    <measurement group_id="O3" value="-39.8" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.0" spread="22.82"/>
                    <measurement group_id="O2" value="-45.3" spread="21.53"/>
                    <measurement group_id="O3" value="-44.8" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.8" spread="23.26"/>
                    <measurement group_id="O2" value="-45.8" spread="20.46"/>
                    <measurement group_id="O3" value="-45.8" spread="20.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="54.86"/>
                    <measurement group_id="O2" value="-46.9" spread="22.66"/>
                    <measurement group_id="O3" value="-37.9" spread="36.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.0" spread="31.19"/>
                    <measurement group_id="O2" value="-48.4" spread="22.14"/>
                    <measurement group_id="O3" value="-44.2" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis</title>
        <description>Subjects answered the following question, “Considering the possible effects of the arthritis, how are you feeling today?” The subject’s response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis</title>
          <description>Subjects answered the following question, “Considering the possible effects of the arthritis, how are you feeling today?” The subject’s response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="8.87"/>
                    <measurement group_id="O2" value="-32.6" spread="27.55"/>
                    <measurement group_id="O3" value="-24.4" spread="25.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="11.27"/>
                    <measurement group_id="O2" value="-43.4" spread="27.47"/>
                    <measurement group_id="O3" value="-35.8" spread="25.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="19.69"/>
                    <measurement group_id="O2" value="-51.3" spread="20.53"/>
                    <measurement group_id="O3" value="-41.9" spread="23.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.0" spread="8.83"/>
                    <measurement group_id="O2" value="-52.1" spread="21.35"/>
                    <measurement group_id="O3" value="-49.8" spread="17.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.0" spread="13.64"/>
                    <measurement group_id="O2" value="-53.0" spread="20.96"/>
                    <measurement group_id="O3" value="-48.7" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5" spread="20.09"/>
                    <measurement group_id="O2" value="-49.6" spread="20.26"/>
                    <measurement group_id="O3" value="-49.6" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.3" spread="11.18"/>
                    <measurement group_id="O2" value="-46.3" spread="26.67"/>
                    <measurement group_id="O3" value="-48.3" spread="22.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="30.24"/>
                    <measurement group_id="O2" value="-50.8" spread="20.78"/>
                    <measurement group_id="O3" value="-40.8" spread="27.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.7" spread="16.80"/>
                    <measurement group_id="O2" value="-55.3" spread="20.51"/>
                    <measurement group_id="O3" value="-51.3" spread="19.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis</title>
        <description>The rheumatologist investigator assessed how the subject’s overall arthritis appeared at the time of the visit. This was an evaluation based on the subject’s disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator’s response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis</title>
          <description>The rheumatologist investigator assessed how the subject’s overall arthritis appeared at the time of the visit. This was an evaluation based on the subject’s disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator’s response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="18.01"/>
                    <measurement group_id="O2" value="-28.5" spread="18.60"/>
                    <measurement group_id="O3" value="-24.1" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="22.28"/>
                    <measurement group_id="O2" value="-34.6" spread="19.39"/>
                    <measurement group_id="O3" value="-33.9" spread="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="30.01"/>
                    <measurement group_id="O2" value="-41.8" spread="21.87"/>
                    <measurement group_id="O3" value="-37.7" spread="24.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.8" spread="21.00"/>
                    <measurement group_id="O2" value="-45.8" spread="22.76"/>
                    <measurement group_id="O3" value="-43.8" spread="21.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.8" spread="23.34"/>
                    <measurement group_id="O2" value="-47.9" spread="20.09"/>
                    <measurement group_id="O3" value="-48.5" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.8" spread="25.29"/>
                    <measurement group_id="O2" value="-45.3" spread="26.81"/>
                    <measurement group_id="O3" value="-47.1" spread="25.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5" spread="25.96"/>
                    <measurement group_id="O2" value="-42.8" spread="22.79"/>
                    <measurement group_id="O3" value="-45.0" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" spread="39.03"/>
                    <measurement group_id="O2" value="-49.5" spread="18.54"/>
                    <measurement group_id="O3" value="-45.8" spread="25.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="20.30"/>
                    <measurement group_id="O2" value="-46.8" spread="25.08"/>
                    <measurement group_id="O3" value="-41.9" spread="24.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)</title>
        <description>The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)</title>
          <description>The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="2.137"/>
                    <measurement group_id="O2" value="-1.68" spread="2.231"/>
                    <measurement group_id="O3" value="-1.52" spread="2.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="2.267"/>
                    <measurement group_id="O2" value="-1.69" spread="2.272"/>
                    <measurement group_id="O3" value="-1.53" spread="2.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.354"/>
                    <measurement group_id="O2" value="-1.70" spread="2.222"/>
                    <measurement group_id="O3" value="-1.56" spread="2.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.351"/>
                    <measurement group_id="O2" value="-1.68" spread="2.235"/>
                    <measurement group_id="O3" value="-1.54" spread="2.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="2.337"/>
                    <measurement group_id="O2" value="-1.69" spread="2.189"/>
                    <measurement group_id="O3" value="-1.56" spread="2.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.387"/>
                    <measurement group_id="O2" value="-1.59" spread="2.336"/>
                    <measurement group_id="O3" value="-1.50" spread="2.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="2.337"/>
                    <measurement group_id="O2" value="-1.15" spread="2.770"/>
                    <measurement group_id="O3" value="-1.20" spread="2.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=4, 7, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="2.037"/>
                    <measurement group_id="O2" value="-1.84" spread="2.461"/>
                    <measurement group_id="O3" value="-1.59" spread="2.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.058"/>
                    <measurement group_id="O2" value="-1.65" spread="2.295"/>
                    <measurement group_id="O3" value="-1.21" spread="2.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg BID</title>
            <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID</title>
            <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>(=sum across Arm/Groups)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.</description>
          <population>Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.239"/>
                    <measurement group_id="O2" value="-0.28" spread="0.376"/>
                    <measurement group_id="O3" value="-0.25" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.329"/>
                    <measurement group_id="O2" value="-0.36" spread="0.381"/>
                    <measurement group_id="O3" value="-0.33" spread="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.359"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.38" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.359"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.38" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.375"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.39" spread="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.359"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.38" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.400"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.40" spread="0.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.640"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.31" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=3, 8, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.573"/>
                    <measurement group_id="O2" value="-0.42" spread="0.433"/>
                    <measurement group_id="O3" value="-0.34" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 5 mg BID</title>
          <description>CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 10 mg BID</title>
          <description>CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>(=sum across Arm/Groups)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Conjunctival deposit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lip erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vaginitis gardnerella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Solar dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

